GlobeNewswire

Nyxoah Reports Third Quarter 2026 Financial and Operating Results
05/11/2026
REGULATED INFORMATION Nyxoah Reports Third Quarter 2026 Financial and Operating Results Global net revenue was €9.2 million driven by 29% sequential U.S. net revenue growth PMA supplement submitted to the FDA to expand [...]
Mobia Medical Reports Third Quarter 2026 Financial Results
05/11/2026
Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining [...]
Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
Proteus™ remains on track for anticipated Q2 2027 commercial launch BRANFORD, Conn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics [...]
Solésence To Report Third Quarter 2026 Financial Results and Host a Conference Call on November 12
05/11/2026
ROMEOVILLE, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]
MacroGenics to Participate in Upcoming Investor Conferences
05/11/2026
ROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, [...]
Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
05/11/2026
DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of [...]
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
05/11/2026
BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced [...]
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
05/11/2026
Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully [...]
Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
05/11/2026
CANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
05/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
05/11/2026
CERRITOS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported [...]
Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates
05/11/2026
Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre [...]
TerrAscend Reports Third Quarter 2026 Financial Results
05/11/2026
Q3 2026 Net Revenue of $68.2 Million, Up 4.8% Year-Over-Year Q3 2026 Gross Profit Margin of 52.3%, Up 20 Basis Points Year-Over-Year Q3 2026 Net Cash Provided from Continuing Operations of $8.8 Million, Representing 17. [...]
Nephros Announces Strong Third Quarter 2026 Financial Results
05/11/2026
Year Over Year Net Revenue Growth of 18% and Core Programmatic Revenue Growth of 8% for the Three Months Ended September 30, 2026 SOUTH ORANGE, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a [...]
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
05/11/2026
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January [...]
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
05/11/2026
Infection is a Major Unmet Need in Plastic and Reconstructive Surgery: Infection risk was cited in all 11 breast research sessions at the American Society of Plastic Surgeons’ annual meeting, with serious infection [...]
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
05/11/2026
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 QUELL-CV, a Phase 2 [...]
Tarsus to Participate in Upcoming Investor Conferences
05/11/2026
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Guggenheim 3 rd Annual [...]
Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
05/11/2026
Company to host a conference call and audio webcast tomorrow at 8:00 a.m. ET TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum